Distribution of funds for colorectal and cervical cancer screening programs in Spain

23

Sep 2022

On September 5, 2022, it was announced that the Interterritorial Council for the Spanish National Health System (CISNS) approved the distribution of funds to the Autonomous Communities for the fight against cancer. The aim is to boost the screening programs for colorectal and cervical cancer. It was outlined that these screenings are essential for the early detection of these pathologies in the target population. The total amount of funds to be distributed is €12 million, €6 million for 2022, and another €6 million for 2023.

As an example, the target population for colorectal cancer screening currently includes men and women aged 50 to 69 years. The screening test is a fecal occult blood test, and the interval between screening tests is two years. In addition to the screening program, in the case of people who meet the criteria of high personal risk or risk of familial or hereditary cancer, the assessment of the individual risk and follow-up is carried out through specific action protocols.

The target population for the cervical cancer screening program are women aged 25 to 65 years. In women aged 25 to 34 years the primary screening test is cytology, which is carried out every three years. In women aged 35 to 65 years, the determination of high-risk human papillomavirus (HPV) is used; further strategy depends on the test results. In addition to the screening program, in the case of women who meet the criteria of high personal risk or risk of familial or hereditary cancer, the assessment of the individual risk and follow-up is carried out through specific action protocols.

The full details in Spanish can be found here and here.

This news is just one of about 300 market access news collected by our team in the subscription services "HTA Alerts" and "Reimbursement Alerts" every two weeks from more than 80 organizations. Access our paid subscription services to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news).

Not ready for a subscription service? Subscribe to our free-of-charge newsletter delivered every second week to get updates about key reimbursement developments in Europe (10-12 news every two weeks). First EU issues of both newsletters are available for download free-of-charge.

The latest related news

22

Mar 2023

A new preeclampsia screening algorithm has been evaluated within the "New Method" framework since 2021. The algorithm helps to predict the risk of preeclampsia in the first trimester based on several parameters, including ultrasound examination and measurement of the Placenta Growth Factor (PIGF). In March 2023, the Decision Forum for "New Method" was held and commissioned to perform the implementation study of a new screening algorithm at St. Olav's Hospital.

Read more

16

Mar 2023

MTRC shares the most relevant and impactful publications in the field of market access and HEOR for medical technologies in Europe through its Publications Digest. In a recent publication, Horgan et al. completed a survey of the status of Next-Generation Sequencing (NGS) in Europe and globally. Based on the feedback from 62 experts, a framework for implementation of the NGS is proposed along with in-depth discussion about current aspects of demand-and supply-side issues, governance and strategy, clinical standardization, awareness and education, equipment used, reimbursement and funding.

Read more

14

Mar 2023

The Ministry of Health has commissioned the Agency for Health Quality and Assessment of Catalonia (AQuAS) to develop, with the collaboration of the various agencies that make up the Spanish Network of Agencies for the Evaluation of Health Technologies and Benefits (RedETS), a specific methodological framework for the evaluation of digital health technologies that would allow a comprehensive assessment of this type of technology. The methodological framework is in the final phase of development.

Read more

10

Mar 2023

In February 2023, the National Institute for Health and Care Excellence (NICE) published two new Interventional Procedure Guidance (transvenous obliteration for gastric varices, biodegradable spacer to reduce rectal toxicity during radiotherapy for prostate cancer), one new Health Technology Evaluation (guided self-help digital cognitive behavioural therapy), and two new Medtech Innovation Briefings (LIVERFASt, and Ambu aScope 4 RhinoLaryngo). Also, one new clinical guideline was published, and one was updated.

Read more

08

Mar 2023

On February 23, 2023, the Innovation Committee at the Federal Joint Committee (G-BA) published the decisions, recommending the transfer to standard care for another three completed projects. The projects relate to preventing the family risk of colorectal carcinoma, shared decision-making in the hospitals, and digitally supported drug therapy management.

Read more